Skip to content

Scholar Rock SRRK Short- term Investments

Short- term Investments at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
Erasca, Inc. logo
Erasca, Inc.ERAS
Corcept Therapeutics logo
Corcept TherapeuticsCORT

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$6.14B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's short- term investments?
Scholar Rock (SRRK) reported short- term investments of $49.4M in Q1 2026.
How has Scholar Rock's short- term investments changed year-over-year?
Scholar Rock's short- term investments decreased by 78.2% year-over-year, from $226.45M to $49.4M.
What is the long-term trend for Scholar Rock's short- term investments?
Over 5 years (2020 to 2025), Scholar Rock's short- term investments has grown at a -24.6% compound annual growth rate (CAGR), from $180.67M to $44.04M.